Lansoprazole is a proton pump inhibitor drug, which prevents the
stomach from producing gastric acid to facilitate treatment of
various gastric disorders. Proton pump inhibitors work on the
mechanism of action, where these act by inhibiting the proton pump,
which is the pivotal area for secretion of H+ ions in the gastric
lumen. Proton pump inhibitors form a covalent bond with proton pump,
deactivating it, leading to lack of H+ ions secretion in the gastric
lumen, thereby inhibiting the production of gastric acid.
Lansoprazole is different from other drug classes available for
treatment of gastroesophageal reflux disease such as antacids, which
act by neutralizing the acid secreted in the stomach. Lansoprazole
acts on this mechanism to treat gastroesophageal reflux disease
(GERD), which is characterized by the backward flow of gastric acid
from the stomach, leading to symptoms such as heartburn and acidity.
The products are available as prescription brands and
over-the-counter drugs (OTC) in various forms.
Report Overview @
https://www.transparencymarketresearch.com/lansoprazole-market.html
The global lansoprazole market is primarily driven by increase in
incidence of gastroesophageal reflux disease (GERD), gastric ulcers,
duodenal ulcers, and other gastric diseases. Rise in demand for
proton pump inhibitors and ongoing clinical trials for the evaluation
of new formulations of lansoprazole aimed at increasing the
efficiency of the drug are the other factors expected to drive the
global lansoprazole market during the forecast period. However, new
drug classes being introduced in the market for the treatment of
gastric diseases such as H2 blockers, antacids, and others, and
increase in patient preference for these drug classes that offer
immediate relief from gastroesophageal reflux disease are expected to
restrain the global lansoprazole market during the forecast period.
The global lansoprazole market can be segmented based on route of
administration, mode of action, distribution channel, and region. In
terms of route of administration, the global market can be bifurcated
into oral and intravenous. The oral segment dominated the global
lansoprazole market in 2016 owing to higher preference for capsule
formulations by patients suffering from mild to moderate
gastroespophageal reflux disease, low cost of oral capsules, and
increase in number of manufacturers in the global market offering
lansoprazole in capsule formulations. Based on mode of action, the
global lansoprazole market can be categorized into immediate release
and sustained release.
Download Report Brochure @
https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=37778
The immediate release segment dominated the global lansoprazole
market in 2016 due to rise in incidence of acute gastroesophageal
reflux disease and low cost of the drugs. However, rise in
prescription base for sustained release lansoprazole along with
increase in number of manufacturers offering products in this segment
is expected to drive the sustained release segment during the
forecast period. In terms of distribution channel, the global
lansoprazole market can be divided into hospital pharmacies, online
pharmacies, and retail pharmacies & drug stores. The retail
pharmacies & drug stores segment dominated the market in 2016,
owing to increase in number of over-the-counter brands of
lansoprazole and ease of access of patients toward retail pharmacies
for treatment of mild to moderate gastroesophageal reflux diseases
(GERD).
The global lansoprazole market can be segmented into five major
regions: North America, Europe, Asia Pacific, Latin America, and
Middle East & Africa. North America dominated the global market
in 2016 due to increase in incidence of GERD in the U.S. and higher
demand for sustained release proton pump inhibitor drugs in the
region. According to the World Gastroenterology Organisation, in
2015, prevalence of GERD ranged from 2.5% to 6.6% in Eastern Asia and
13.8% to 25.8% in North America.
Pre-Book Full Report @
https://www.transparencymarketresearch.com/checkout.php?rep_id=37778<ype=S
Key players operating in the global lansoprazole market include Teva
Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company
Limited, Perrigo Company plc, and Sun Pharmaceutical Industries Ltd.
About Us
Transparency Market Research (TMR) is a market intelligence company,
providing global business information reports and services. Our
exclusive blend of quantitative forecasting and trends analysis
provides forward-looking insight for thousands of decision makers.
TMR’s experienced team of analysts, researchers, and consultants,
use proprietary data sources and various tools and techniques to
gather, and analyze information. Our business offerings represent the
latest and the most reliable information indispensable for businesses
to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such
as pharmaceuticals, chemicals, energy, food & beverages,
semiconductors, med-devices, consumer goods and technology. These
reports provide in-depth analysis and deep segmentation to possible
micro levels. With wider scope and stratified research methodology,
TMR’s syndicated reports strive to provide clients to serve their
overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment